Resolves YES if, by December 31, 2031, a peer-reviewed publication or an official Dog Aging Project / TRIAD announcement reports the trial's primary lifespan endpoint with a statistically significant benefit of rapamycin over placebo (p < 0.05 or the trial's pre-specified significance criterion). Reports of healthspan or secondary endpoints only, a null or harmful lifespan result, or no primary lifespan result by the deadline all resolve NO. Background: TRIAD (Test of Rapamycin in Aging Dogs) is a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged companion dogs with lifespan and healthspan endpoints, described by its investigators as the first rigorous test of a drug against biological aging with such endpoints outside the laboratory in any species (GeroScience 2025). NIH RePORTER lists R01AG090843 (Texas A&M AgriLife Research) with a project period of December 2024 to November 2029. Two earlier placebo-controlled rapamycin trials in companion dogs (24 dogs for 10 weeks, 2017; 17 dogs for 6 months, 2023) reported no clinically significant adverse events. Companion question: Will a randomized human trial of an anti-aging drug with all-cause mortality or lifespan as its primary endpoint be registered on ClinicalTrials.gov before January 1, 2030? Sources: pubmed.ncbi.nlm.nih.gov RePORT ⟩ RePORTER https://w0lph.github.io/k9/trials/triad-rapamycin.html

Test of Rapamycin in Aging Dogs (TRIAD): canine aging trial registry record

TRIAD is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test whether rapamycin prolongs lifespan and improves healthspan metrics in healthy, middle-aged, large-breed dogs recruited from Dog Aging Project participants. The hypothesis is that a one-year co